A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
12/2007
12/21/2007	WO2007145457A1 N-terminal modified peg-trail, method for preparing and uses thereof
12/21/2007	WO2007145344A1 Ophthalmic composition for soft contact lens comprising terpenoid
12/21/2007	WO2007145306A1 Element having long blood-circulating time which is degradable selectively in tumor tissue
12/21/2007	WO2007145191A1 Coated tablet
12/21/2007	WO2007145158A1 Hollow-fiber-like organic nanotube and process for production thereof
12/21/2007	WO2007144985A1 Use of rpn2 gene expression inhibitor
12/21/2007	WO2007144709A2 Leptomycin derivatives
12/21/2007	WO2007144189A2 Compositions based on hyperbranched condensation polymers and novel hyperbranched condensation polymers
12/21/2007	WO2007144140A1 A process for the preparation of poly-alfa-glutamic acid and derivatives thereof
12/21/2007	WO2007144048A2 Presentation form for the oral administration of phenothiazine dyes, its production and use
12/21/2007	WO2007143851A1 Fermented plant extracts, methods of production and uses
12/21/2007	WO2007143848A1 Poly (vinyl alcohol) polymers, uses and preparation thereof
12/21/2007	WO2007124598A3 Softgel capsules with phytosterols and/or phytostanols and optionlly omega polyunstaurated fatty acids
12/21/2007	WO2007123800A3 Stabilized pentosan polysulfate (pps) formulations and methods of analyzing them
12/21/2007	WO2007120544A3 Compositions comprising pyruvate alkyl esters and uses thereof
12/21/2007	WO2007106468A3 Formulations of sitaxsentan sodium
12/21/2007	WO2007095043A3 Pharmaceutical formulations
12/21/2007	WO2007076448A3 Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
12/21/2007	WO2007064661A3 Bifunctional metal chelating conjugates
12/21/2007	WO2007001744B1 Methods and compositions for enhancing vascular access
12/21/2007	WO2006134148A3 Transglutaminase mediated conjugation of growth hormone
12/21/2007	CA2836545A1 Pharmaceutical composition
12/21/2007	CA2690706A1 Poly (vinyl alcohol) polymers, uses and preparation thereof
12/21/2007	CA2682755A1 Fermented plant extracts, methods of production and uses
12/21/2007	CA2656077A1 A process for the preparation of poly-alpha-glutamic acid and derivatives thereof
12/21/2007	CA2655355A1 Use of rpn2 gene expression inhibitor
12/21/2007	CA2654990A1 Pharmaceutical formulations and compositions of a selective antagonist of either cxcr2 or both cxcr1 and cxcr2 and methods of using the same for treating inflammatory disorders
12/21/2007	CA2654799A1 Large-particle cyclodextrin inclusion complexes and methods of preparing same
12/21/2007	CA2654322A1 Leptomycin derivatives
12/21/2007	CA2654073A1 Liposome-mediated native chemical ligation
12/21/2007	CA2653782A1 Topical compositions
12/20/2007	US20070293659 Immobilization of glycoproteins
12/20/2007	US20070293557 Anticancer compositions, and methods of making and using the same
12/20/2007	US20070293517 Derivatives Of Chemotherapeutic Agents With A Formaldehyde Releasing Moiety
12/20/2007	US20070293468 Reacting indazolium hydrochloride with Sodium tetrachlorobisindazoleruthenate(III) to form trans-Indazolium [tetrachlorobisindazoleruthenate(III)] (KP1019), and sodium chloride; both highly effective and water soluble; bioavailability; cancer treatment
12/20/2007	US20070293423 Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
12/20/2007	US20070293419 Stable, Aqueous Solution of Human Erythropoietin, Not Containing Serum Albumin
12/20/2007	US20070293418 Therapeutic amino acid sequences for use in treatment and prevention of viral, infectious, cancerous, diabetic, incontinent, hypertensive and nervous system disorders
12/20/2007	US20070292931 Degradable Heterobifunctional Poly(ethylene glycol) Acrylates and Gels and Conjugates Derived Therefrom
12/20/2007	US20070292526 Combining a reverse micelle solution with silica-, alumina-, titanium dioxide-, iron oxide-, and/or zirconium dioxide-based gel precursor solution containing catalyst, a condensation agent (H2O), and polar solvent, one of which contains an active material, to generate droplets containing active material
12/20/2007	US20070292525 Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use
12/20/2007	US20070292524 Delivery vehicle containing nanoparticles
12/20/2007	US20070292516 Multifunctional biocompatible hydrophilic gel and the method of gel manufacture
12/20/2007	US20070292515 Solid dosage form containing a taste masked active agent
12/20/2007	US20070292506 Sustained release formulations
12/20/2007	US20070292494 Carbohydrate-Derivatized Liposomes for Targeting Cellular Carbohydrate Recognition Domains of Ctl/Ctld Lectins, and Intracellular Delivery of Therapeutically Active Compounds
12/20/2007	US20070292483 Reducing muscle soreness with glucosamine compositions
12/20/2007	US20070292482 Delivery System
12/20/2007	US20070292481 Packaging of Food Products with Pullulan Films
12/20/2007	US20070292480 Delivery System for Ingestible Components
12/20/2007	US20070292477 Association of Antimicrobial Compounds with Surfaces and Polymers
12/20/2007	US20070292462 Surfactant, and an emulsion-type cosmetic composition and a liposome containing said surfactant
12/20/2007	US20070292457 Electrical Nutritional Supplement
12/20/2007	US20070292454 Therapeutic calcium phosphate particles and methods of manufacture and use
12/20/2007	US20070292441 Tumor Specific Antibody
12/20/2007	US20070292436 Immunogenic proteoliposomes, and uses thereof
12/20/2007	US20070292353 Nanoparticles Comprising an Intracellular Targeting Element and Preparation and Use Thereof
12/19/2007	EP1867673A1 Coordination compound composed of diaminocyclohexane platinum (ii) and block copolymer and anti-cancer agent comprising the same
12/19/2007	EP1867657A1 Process for the preparation of poly-a-glutamic acid and derivatives thereof
12/19/2007	EP1867633A1 Polyamine analogues as therapeutic and diagnostic agents
12/19/2007	EP1867343A2 Novel compounds
12/19/2007	EP1867334A1 Method of relieving or avoiding side effect of steroid compound
12/19/2007	EP1867333A1 Pharmaceutical composition comprising condensed indole compound
12/19/2007	EP1867330A1 Method of improving the storage stability of substance
12/19/2007	EP1867321A2 A pharmaceutical product adapted for oral transmucosal administration comprising a pharmaceutical agent
12/19/2007	EP1866416A2 Delivery systems and methods for diagnosing and treating cardiovascular diseases
12/19/2007	EP1866415A2 A cysteine-containing peptide tag for site-specific conjugation of proteins
12/19/2007	EP1866332A1 Use of crotamine, kit and composition
12/19/2007	EP1865991A2 Cytotoxic compounds and conjugates comprising duocarmycins with cleavable substrates
12/19/2007	EP1865990A1 Method of treating or preventing type-2 diabetes
12/19/2007	EP1865989A2 Peg-poly(ortho ester) graft copolymers and pharmaceutical compositions
12/19/2007	EP1865988A2 Peg-polyacetal diblock and triblock copolymers and pharmaceutical compositions
12/19/2007	EP1865986A2 Anti-ctla-4 antibody compositions
12/19/2007	EP1865968A2 Topical formulations of borinic acid antibodies and their methods of use
12/19/2007	EP1865967A2 Compounds, compositions and methods for the treatment of viral infections and other medical disorders
12/19/2007	EP1865934A1 Ejection liquid, ejection method, method of making droplets from liquid, cartridge and ejection device
12/19/2007	EP1865928A1 Nanoparticulate biphosphonate compositions
12/19/2007	EP1865925A1 Buccal delivery system
12/19/2007	EP1865839A2 Functionalized magnetic nanoparticles and methods of use thereof
12/19/2007	EP1865773A2 Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
12/19/2007	EP1784172A4 Cancer chemotherapy
12/19/2007	EP1682124B1 Pharmaceutical compositions based on idazoxan salt or one of its polymorphs
12/19/2007	EP1654003B1 Preventative effects of morinda citrifolia on mammary breast cancer
12/19/2007	EP1551370B1 Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
12/19/2007	EP1480651B1 Aerosol formulations containing esters of 3,17-dihydroxy oestratriene derivatives for pulmonary delivery
12/19/2007	EP1434567B1 Method for preparing a compound for interaction of active substances with a porous support using supercritical fluid
12/19/2007	EP1420802B1 Increased solubility flavanolignan preparations
12/19/2007	EP1411921B1 Pharmaceutical compositions containing terbinafine and use thereof
12/19/2007	EP1318788B1 Solid dose nanoparticulate compositions
12/19/2007	EP1204427A4 The nasal transmucosal delivery of peptides conjugated with biocompatible polymers
12/19/2007	EP1194166B1 Aqueous immunologic adjuvant compositions of monophosphoryl lipid a
12/19/2007	EP1091757B1 Alpha emitting constructs and uses thereof
12/19/2007	EP0941079B1 Bioceramic compositions
12/19/2007	CN101090980A 经修饰的人类生长激素 Modified human growth hormone
12/19/2007	CN101090883A Substituted hydroxyethylamines
12/19/2007	CN101090738A Matrix type sustained-release preparation containing basic drug or salt thereof
12/19/2007	CN101090737A Matrix type sustained-release preparation
12/19/2007	CN101090736A Stable emulsion compositions for intravenous administration having preservative efficacy
12/19/2007	CN101090735A Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms
12/19/2007	CN101090727A Intraoral disintegration type solid preparation containing povidone iodine

1 ... 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 ... 1712